Search research articles
Contact Us
Filters
Showing results (11-20 of 16) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 16 results.
Biorxiv : the Preprint Server for Biology
|
December 12, 2025
HTS-Oracle: Experimentally validated AI-enabled prioritization for generalizable small molecule hit discovery
Hossam Nada, Laura Calvo-Barreiro, Natalie Fuchs, et al.
European Journal of Medicinal Chemistry
|
May 21, 2022
New peptidomimetic rhodesain inhibitors with improved selectivity towards human cathepsins
Sascha Jung, Natalie Fuchs, Christoph Grathwol, et al.
ACS Infectious Diseases
|
April 30, 2024
Dual Strategy to Design New Agents Targeting <i>Schistosoma mansoni</i>: Advancing Phenotypic and <i>Sm</i>CB1 Inhibitors for Improved Efficacy
Natalie Fuchs, Robert A Zimmermann, Marvin Schwickert, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)
|
June 14, 2023
Next Generation of Fluorometric Protease Assays: 7-Nitrobenz-2-oxa-1,3-diazol-4-yl-amides (NBD-Amides) as Class-Spanning Protease Substrates
Hannah Maus, Patrick Müller, Mergim Meta, et al.
ACS Chemical Biology
|
March 9, 2022
Identification, Characterization, and Synthesis of Natural Parasitic Cysteine Protease Inhibitors: Pentacitidins Are More Potent Falcitidin Analogues
Stephan Brinkmann, Sandra Semmler, Christian Kersten, et al.
Journal of Medicinal Chemistry
|
August 11, 2021
Fluorovinylsulfones and -Sulfonates as Potent Covalent Reversible Inhibitors of the Trypanosomal Cysteine Protease Rhodesain: Structure-Activity Relationship, Inhibition Mechanism, Metabolism, and In Vivo Studies
Sascha Jung, Natalie Fuchs, Patrick Johe, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 16) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 16 results.
Biorxiv : the Preprint Server for Biology
|
December 12, 2025
HTS-Oracle: Experimentally validated AI-enabled prioritization for generalizable small molecule hit discovery
Hossam Nada, Laura Calvo-Barreiro, Natalie Fuchs, et al.
European Journal of Medicinal Chemistry
|
May 21, 2022
New peptidomimetic rhodesain inhibitors with improved selectivity towards human cathepsins
Sascha Jung, Natalie Fuchs, Christoph Grathwol, et al.
ACS Infectious Diseases
|
April 30, 2024
Dual Strategy to Design New Agents Targeting <i>Schistosoma mansoni</i>: Advancing Phenotypic and <i>Sm</i>CB1 Inhibitors for Improved Efficacy
Natalie Fuchs, Robert A Zimmermann, Marvin Schwickert, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)
|
June 14, 2023
Next Generation of Fluorometric Protease Assays: 7-Nitrobenz-2-oxa-1,3-diazol-4-yl-amides (NBD-Amides) as Class-Spanning Protease Substrates
Hannah Maus, Patrick Müller, Mergim Meta, et al.
ACS Chemical Biology
|
March 9, 2022
Identification, Characterization, and Synthesis of Natural Parasitic Cysteine Protease Inhibitors: Pentacitidins Are More Potent Falcitidin Analogues
Stephan Brinkmann, Sandra Semmler, Christian Kersten, et al.
Journal of Medicinal Chemistry
|
August 11, 2021
Fluorovinylsulfones and -Sulfonates as Potent Covalent Reversible Inhibitors of the Trypanosomal Cysteine Protease Rhodesain: Structure-Activity Relationship, Inhibition Mechanism, Metabolism, and In Vivo Studies
Sascha Jung, Natalie Fuchs, Patrick Johe, et al.
Page
of 2